Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Category Archives: Actos & Bladder Cancer

Subscribe to Actos & Bladder Cancer RSS Feed

Actos Manufacturer to Pay Millions in Cancer Lawsuit Settlement

Posted in Actos & Bladder Cancer

Last week, the pharmaceutical company, Takeda, was ordered to pay $1.3 million in punitive damages to a former Philadelphia schoolteacher who “argued the drugmaker’s Actos diabetes medicine caused his bladder cancer”, Japan Times writes. Only a few days earlier, that man was awarded over $2.3 million in compensatory damages. According to that Japan Times article,… Continue Reading

2012 – “Bladder cancer is a real risk with [Actos]”

Posted in Actos & Bladder Cancer

A recent article published as an editorial in Diabetes Research and Clinical Practice by JA Johnson et al. titled “Balancing the risks and benefits for pioglitazone in type 2 diabetes.” set out to clarify some of the risks and benefits of using the diabetes drug Actos (pioglitazone). The authors state “All therapeutic choices need to… Continue Reading

2012 – Long-term Actos use raises risk for bladder cancer 60-80%

Posted in Actos & Bladder Cancer

In 2012, an article was published in Urology titled “Association between pioglitazone and urothelial bladder cancer.” by Y. Barbalat et al. that aimed to “present the current literature reporting the association between pioglitazone and bladder cancer.”  To be clear, “pioglitazone” is the chemical name for the diabetes drug, Actos, manufactured by Takeda Pharmaceutical Co. and… Continue Reading

2013 – Actos associated with 56% increased risk for bladder cancer

Posted in Actos & Bladder Cancer

A recent article published in the August, 2013 edition of Hepatology by CH Chang et al. titled “Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus” studied the connection between certain diabetes drugs and cancer.  Thiazolidinediones are a class of diabetes drugs including Actos and others. This team of researchers… Continue Reading

Actos Manufacturers Slated to Pay $9 Billion in Damages

Posted in Actos & Bladder Cancer

Recently, a federal court has ordered that the manufacturers of the diabetes drug Actos (pioglitazone hydrochloride, by Takeda Pharmaceutical Co. and Eli Lilly & Co.) pay $9 billion in damages when it was determined that these companies failed to warn the public of cancer risks associated with their medication. Though some legal experts believe that… Continue Reading

2011 – Doctor to advocate for Actos paid by manufacturer

Posted in Actos & Bladder Cancer

In 2011, Robert Elford Ryder published a report in the medical journal The Lancet titled “Pioglitazone and bladder cancer” which discusses the link between diabetes drug Actos (Tadeka Pharmaceuticals, Inc.) and bladder cancer. At the outset of his piece, Ryder states “In June, 2011, the French and German regulatory bodies suspended pioglitazone over the risk… Continue Reading

2013 – Large study shows Actos raises risk for bladder cancer 30%

Posted in Actos & Bladder Cancer

In 2013, a team of researchers led by MT Bazelier published a paper titled “Use of thiazolidinediones and risk of bladder cancer: disease or drugs?”, where it is stated “Pioglitazone, a drug for the treatment of type 2 diabetes mellitus has been associated with bladder cancer in observational studies” but that “Diabetes mellitus itself has… Continue Reading

2012 – Actos shown to increase risk for bladder cancer

Posted in Actos & Bladder Cancer

In 2012, a study was published titled “Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.” that aimed to evaluate the connection between the thiazolidinedione class of diabetes drugs (e.g. Actos) and bladder cancer.  The study appeared in Journal of the National Cancer Institute and was prepared by R. Mamtani… Continue Reading

2011 – FDA: Actos raises risk for bladder cancer by 430%

Posted in Actos & Bladder Cancer

A 2011 article published in Diabetes Care by C. Piccinni et al. titled “Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.” set out to “analyze the association between pioglitazone [(Actos)] use and bladder cancer through a spontaneous adverse event reporting system for medications.” To obtain data for this study,… Continue Reading

2012 – Long term Actos use doubles risk for bladder cancer

Posted in Actos & Bladder Cancer

In 2012, an article by L. Azoulay et al. titled “The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.” aimed to “determine if the use of pioglitazone is associated with an increased risk of incident bladder cancer in people with type 2 diabetes.”  (“Pioglitazone” is… Continue Reading

2011 – Actos dramatically raises risk for bladder cancer

Posted in Actos & Bladder Cancer

In 2011, a report by JD Lewis et al. titled “Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.” published in Diabetes Care states “studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy” and as such, this was a report… Continue Reading

2013 – Two years of Actos use found to double risk for bladder cancer

Posted in Actos & Bladder Cancer

In August 2013, an article titled “Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.” was published by F.Y. Hsiao et al. in the medical journal Drug Safety that aimed to evaluate the connection between rosiglitazone (Avandia) and bladder cancer and between pioglitazone (Actos) and bladder cancer.  The… Continue Reading

2013 – Risk for bladder cancer associated with Actos ranges from 21% to 251% increase

Posted in Actos & Bladder Cancer

In 2013, a team of researchers led by RM Turner published a report in British Journal of Clinical Pharmacology that evaluated the connection between the thiazolidinedione class of drugs and the onset of bladder cancer.  Drugs in that class include diabetes drugs Avandia and Actos. Evaluating 18 previously-conducted studies (13 observational studies and 5 randomized… Continue Reading

2013 – Study shows Actos use raises risk for bladder cancer by 23%

Posted in Actos & Bladder Cancer

In 2013, a report by M. Ferwana et al. titled “Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.” was published in Diabetes Medicine that sought to evaluate the connection between the diabetes drug Actos and new-onset bladder cancer. Living up to its name, this report reviewed data from six previous studies including… Continue Reading

2012 – Huge study links Actos and bladder cancer

Posted in Actos & Bladder Cancer

In 2012, a study by Z. Zhu et al. titled “Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.” aimed to “examine the association between pioglitazone therapy and bladder cancer in patients with diabetes.”  To be clear, “pioglitazone” is the chemical name for the diabetes drug Actos, manufactured by Takeda… Continue Reading

2013 – “Increased risk of bladder cancer” associated with Actos

Posted in Actos & Bladder Cancer

An article published in a 2013 edition of Tumour Biology titled “Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.” by S. He et al. aimed to determine the risk for bladder cancer associated with use of pioglitazone (Actos; Tadeka Pharmaceuticals, Inc.). The authors of this paper write… Continue Reading

2012 – Actos associated with 22-75% increased risk for bladder cancer

Posted in Actos & Bladder Cancer

In 2012, A. Neumann et al. published a study titled “Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.” in Diabetologica that studied the risk for bladder cancer among French diabetic patients using Actos (pioglitazone), a drug used to control blood sugar manufactured by Tadeka Pharmaceuticals, Inc. According to… Continue Reading

Washington State Actos Cases

Posted in Actos & Bladder Cancer

If anyone in Washington is looking for help with a potential Actos bladder cancer case, give me a call.  I have an office in Redmond and am accepting cases from people all across the state, including as far away as Spokane and as close as Bellevue.  I am happy to help anyone who is looking… Continue Reading

I’m Now Able to Help Individuals Who Developed Bladder Cancer While Taking Actos

Posted in Actos & Bladder Cancer

About a year ago I wrote a quick blog post about whether Actos causes bladder cancer.  At the time, I wasn’t certain whether there was enough evidence to support filing an Actos bladder cancer lawsuit. I’m now convinced that there is credible medical evidence that shows that Actos causes bladder cancer.  I’m therefore accepting cases… Continue Reading